IXHLライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:45):

Stats
本日の出来高	10 535.00
平均出来高	321 558
時価総額	38.09M
EPS	$0 ( 2024-02-25 )
次の収益日	( $0 ) 2024-07-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.73
ATR14	$0.0240 (1.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Valentine Troy	Buy	670 000	Common Stock
2023-12-21	Widdows Peter	Buy	100 000	Common Stock
2023-12-21	Latham Joel	Buy	1 340 000	Common Stock
2023-12-21	Anastassov George	Buy	100 000	Common Stock
2023-12-21	Clark Robert	Buy	100 000	Common Stock

INSIDER POWER
89.25
Last 27 transactions
Buy: 2 310 000 \| Sell: 136 337

Incannex Healthcare 相関

10 最も正の相関
GNUS	0.919
CATB	0.915
TTOO	0.915
TUEM	0.913
LSXMA	0.911
LSXMK	0.91
AGEN	0.903
SIRI	0.902
ACRS	0.902
JKHY	0.897

10 最も負の相関
EBSB	-0.892
CIIG	-0.891
CPTA	-0.883
SCR	-0.88
BTAQ	-0.878
GRIL	-0.876
ASRT	-0.874
PTOC	-0.873
FRSG	-0.873
GPACU	-0.871

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Incannex Healthcare 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.420

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.420

FY	2022
収益:	$0
総利益:	$-6 338.00 (0.00 %)
EPS:	$-0.320

FY	2021
収益:	$1.90M
総利益:	$985 628 (51.94 %)
EPS:	$-0.169

Financial Reports:

No articles found.

Incannex Healthcare

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.